ArticlePloS one2013
Anti-obesity effect of Lactobacillus gasseri BNR17 in high-sucrose diet-induced obese mice.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Role of gut microbiota in type 2 diabetes pathophysiology.EBioMedicine · 2020Pooled it
- Trial
- The Gut-Brain Axis: A Critical Link between Type 2 Diabetes and Parkinson's disease.Probiotics and antimicrobial proteins · 2026Review
- Article
- Anti-obesity effect ofFood science and biotechnology · 2026Article
- Review
- Using Gut Microbiota Modulation as a Precision Strategy Against Obesity.International journal of molecular sciences · 2025Review
- Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics.World journal of hepatology · 2025Review
- Gut-Microbiota-Driven Lipid Metabolism: Mechanisms and Applications in Swine Production.Metabolites · 2025Review
- Functional efficacy ofFuture microbiology · 2025Article
- Therapeutic Role of Probiotics Against Environmental-Induced Hepatotoxicity: Mechanisms, Clinical Perspectives, Limitations, and Future.Probiotics and antimicrobial proteins · 2025Review
- Therapeutic Strategies to Modulate Gut Microbial Health: Approaches for Chronic Metabolic Disorder Management.Metabolites · 2025Review
- Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications.International journal of molecular sciences · 2025Review
- In-depth Microbiological Characterization of Urine From Subjects With Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2024Article
- Managing Type 2 Diabetes Mellitus via the Regulation of Gut Microbiota: A Chinese Medicine Perspective.Nutrients · 2024Review
- The Role of Gut Microbiota in the Onset and Progression of Obesity and Associated Comorbidities.International journal of molecular sciences · 2024Review
- Characterization of Human Breast Milk-DerivedAntibiotics (Basel, Switzerland) · 2024Article
- Lactobacillus gasseri BNR17 and Limosilactobacillus fermentum ABF21069 Ameliorate High Sucrose-Induced Obesity and Fatty Liver via Exopolysaccharide Production and β-oxidation.Journal of microbiology (Seoul, Korea) · 2024Article
- Curcumin and Gut Microbiota: A Narrative Overview with Focus on Glycemic Control.International journal of molecular sciences · 2024Review
- Can modulation of gut microbiota affect anthropometric indices in patients with non-alcoholic fatty liver disease? An umbrella meta-analysis of randomized controlled trials.Annals of medicine and surgery (2012) · 2024Review
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previously, we reported that Lactobacillus gasseri BNR17 (BNR17), a probiotic strain isolated from human breast milk, inhibited increases in body weight and adipocyte tissue weight in high-sucrose diet-fed Sprague-Dawley (SD) rats and reduced glucose levels in type 2 diabetes mice. In the current study, we conducted further experiments to extend these observations and elucidate the mechanism involved. C57BL/6J mice received a normal diet, high-sucrose diet or high-sucrose diet containing L. gasseri BNR17 (10(9) or 10(10) CFU) for 10 weeks. The administration of L. gasseri BNR17 significantly reduced the body weight and white adipose tissue weight regardless of the dose administered. In BNR17-fed groups, mRNA levels of fatty acid oxidation-related genes (ACO, CPT1, PPARα, PPARδ) were significantly higher and those of fatty acid synthesis-related genes (SREBP-1c, ACC) were lower compared to the high-sucrose-diet group. The expression of GLUT4, main glucose transporter-4, was elevated in BNR17-fed groups. L. gasseri BNR17 also reduced the levels of leptin and insulin in serum. These results suggest that the anti-obesity actions of L. gasseri BNR17 can be attributed to elevated expression of fatty acid oxidation-related genes and reduced levels of leptin. Additionally, data suggested the anti-diabetes activity of L. gasseri BNR17 may be to due elevated GLUT4 and reduced insulin levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.